Ryan J. Watts Ph.D.
Net Worth
Last updated:
What is Ryan J. Watts Ph.D. net worth?
The estimated net worth of Dr. Ryan J. Watts Ph.D. is at least $47,036,634 as of 18 Oct 2024. He owns shares worth $3,489,944 as insider, has earned $34,796,690 from insider trading and has received compensation worth at least $8,750,000 in Denali Therapeutics Inc..
What is the salary of Ryan J. Watts Ph.D.?
Dr. Ryan J. Watts Ph.D. salary is $1,250,000 per year as Co-Founder, Pres, Chief Executive Officer & Director in Denali Therapeutics Inc..
How old is Ryan J. Watts Ph.D.?
Dr. Ryan J. Watts Ph.D. is 49 years old, born in 1976.
What stocks does Ryan J. Watts Ph.D. currently own?
As insider, Dr. Ryan J. Watts Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | Co-Founder, Pres, Chief Executive Officer & Director | 235,807 | $14.8 | $3,489,944 |
What does Denali Therapeutics Inc. do?
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Ryan J. Watts Ph.D. insider trading
Denali Therapeutics Inc.
Dr. Ryan J. Watts Ph.D. has made 69 insider trades between 2018-2024, according to the Form 4 filled with the SEC. Most recently he sold 40,000 units of DNLI stock worth $1,107,600 on 18 Oct 2024.
The largest trade he's ever made was exercising 88,334 units of DNLI stock on 4 Jan 2021. As of 18 Oct 2024 he still owns at least 235,807 units of DNLI stock.
Denali Therapeutics key executives
Denali Therapeutics Inc. executives and other stock owners filed with the SEC:
- Dr. Alexander O. Schuth M.D. (52) Co-Founder, Chief Operating Officer & Sec.
- Dr. Carole Ho (52) Chief Medical Officer & Head of Devel.
- Dr. Marc Tessier-Lavigne Ph.D. (65) Co-Founder, Chairman of Scientific Advisory Board & Independent Director
- Dr. Ryan J. Watts Ph.D. (49) Co-Founder, Pres, Chief Executive Officer & Director
- Mr. Steve Edward Krognes (57) Chief Financial Officer & Treasurer